Home » Inhibitex Obtains HCV Polymerase Inhibitors License
Inhibitex Obtains HCV Polymerase Inhibitors License
Inhibitex has entered into an exclusive worldwide license agreement with the UK’s Cardiff University and Katholieke Universiteit in Belgium covering a series of hepatitis C virus (HCV) polymerase inhibitors in exchange for an upfront license fee, future milestone payments and royalties on future net sales.
The compounds include a series of nucleoside analogs that inhibit NS5b, a critical enzyme in the life cycle of HCV. In vitro studies using a HCV genotype 1b subgenomic replicon system demonstrate these nucleoside analogues are among the most potent HCV polymerase inhibitors in development, Inhibitex said.
Additional financial details were not disclosed.
Upcoming Events
-
07May
-
14May
-
30May